Notizie AIOM – anno XV
FDA Puts Clinical Holds on “Off-the-Shelf” CAR-T Trials
September 5, 2017 - Following the death of a 78-year-old man being treated for blastic plasmacytoid dendritic cell neoplasm (BPDCN), the FDA placed clinical holds on 2 phase I trials investigating a gene-edited allogeneic CAR T-cell (UCART) therapy known as UCART123. The ...Leggi tutto
Web-app
Una nuova web-app gratuita, in otto lingue, per computer, tablet e smartphone sul melanoma è disponibile sul sito del Corriere della Sera in collaborazione con l'Associazione Italiana di Oncologia Medica (leggi e scarica). Strumento interattivo in due versioni, per ...Leggi tutto
FDA approves Gemtuzumab Ozogamicin for treatment of acute myeloid leukemia
September 1, 2017 - The U.S. Food and Drug Administration today approved gemtuzumab ozogamicin for the treatment of adults with newly diagnosed acute myeloid leukemia whose tumors express the CD33 antigen (CD33-positive AML). The FDA also approved gemtuzumab ozogamicin for ...Leggi tutto
FDA clears mammography device with option for patient-assisted compression
September 1, 2017 - Today, the U.S. Food and Drug Administration cleared the first 2D digital mammography system that allows patients to increase or decrease the amount of compression applied to their own breast before the mammogram x-ray is taken. "Regular mammograms are ...Leggi tutto
FDA Grants LN-144 Fast Track Status for Melanoma
September 1, 2017 - The FDA has granted LN-144, an adoptive cell therapy that uses tumor-infiltrating lymphocyte (TIL) technology developed by Iovance Biotherapeutics, a fast track designation for the treatment of patients with advanced melanoma. The designation is based ...Leggi tutto
Role of Cytotoxic Tumor-Infiltrating Lymphocytes in Predicting Outcomes in Metastatic HER2-Positive Breast Cancer: A Secondary Analysis of a Randomized Clinical Trial
Accumulating evidence indicates that tumor-infiltrating lymphocytes (TILs) are associated with clinical outcomes and may predict the efficacy of chemotherapy and human epidermal growth factor receptor 2 (HER2, encoded by the gene ERBB2)-targeted therapy in patients with ...Leggi tutto